Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Visually Interpretable Histopathology-Based Immune Model Predicts T-effector Biology and Response to Immune checkpoint inhibition in Clear Cell Renal Cell Carcinoma Clinical Trial and Contemporary Real-World Datasets.

bioRxiv : the preprint server for biology·2026

Same author

Pediatric fibromuscular dysplasia presenting with acute right lower extremity limb ischemia requiring endovascular treatment and amputation - a case report.

BMC pediatrics·2026

Same author

p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors.

Cancer cell·2026

Same author

Histological features of liver biopsy in patients with COVID-19: a single institution experience with long term follow-up outcome.

Diagnostic pathology·2026

Same author

Surveillance Alone After a Subtotal Resection of Disseminated Juvenile Xanthogranuloma.

Pediatric blood & cancer·2026

Same author

Radiologic, Pathologic, and Deep Learning Predictors of Response to Immune Checkpoint Blockade in Renal Cell Carcinoma Patients Undergoing Post-Treatment Nephrectomy.

medRxiv : the preprint server for health sciences·2025

Search research articles

Related Experiment Video

Updated: Jun 15, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

EXPANDED NEWBORN SCREENING: A REVIEW FOR THE PEDIATRIC PATHOLOGIST.

Dinesh Rakheja¹, Ralph J Deberardinis

¹1 The University of Texas Southwestern Medical Center.

Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society

|March 18, 2010

Summary

This study investigated the impact of a novel therapeutic agent on disease progression. Results indicate a significant reduction in key disease markers, suggesting therapeutic potential.

More Related Videos

State of the Art Cranial Ultrasound Imaging in Neonates

State of the Art Cranial Ultrasound Imaging in Neonates

Published on: February 2, 2015

Related Experiment Videos

Last Updated: Jun 15, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

State of the Art Cranial Ultrasound Imaging in Neonates

State of the Art Cranial Ultrasound Imaging in Neonates

Published on: February 2, 2015

Area of Science:

Biomedical Research
Pharmacology

Background:

The studied disease represents a significant unmet medical need.
Current treatments have limitations in efficacy and side effect profiles.

Purpose of the Study:

To evaluate the efficacy and safety of a novel compound.
To determine the optimal dosage for therapeutic intervention.

Main Methods:

A randomized, double-blind, placebo-controlled trial was conducted.
Participants received varying doses of the investigational drug or placebo.
Biomarkers and clinical outcomes were assessed over a 12-week period.

Main Results:

The investigational drug demonstrated a statistically significant reduction in disease activity compared to placebo.
Key safety parameters were comparable between the drug and placebo groups.
Dose-dependent effects were observed, with higher doses showing greater efficacy.

Conclusions:

The novel therapeutic agent shows promising efficacy and a favorable safety profile.
Further investigation in larger patient populations is warranted.